Trial · NCT00507429
Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
NCT00507429, Phase 2, Phase 3, Terminated, Mateon Therapeutics; results first posted 2014-06-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer. Trials, record NCT00507429. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00507429
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
- NCT number
- NCT00507429
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 80 participants, actual
- Lead sponsor
- Mateon Therapeutics
- Conditions
- Anaplastic Thyroid Cancer
- Interventions
- CA4P, paclitaxel, carboplatin
- First posted
- 2007-07-26
- Last updated
- 2014-06-09
- Results first posted
- 2014-06-09
- Limitations and caveats
- The study was to enroll 180 subjects. Enrollment was terminated early due to low accrual rate. Eighty subjects were enrolled.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival | From randomization to date last known alive | |
| Secondary | To Determine Progression Free Survival | from randomization through end of study visit | |
| Secondary | To Determine Percentage of 1 Year Survival | from randomization through end of study visit |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival | From randomization to date last known alive | All randomized subjects (the Intent-to-treat population) included in the analysis | months | MEDIAN |
| SECONDARY | To Determine Progression Free Survival | from randomization through end of study visit | |||
| SECONDARY | To Determine Percentage of 1 Year Survival | from randomization through end of study visit | Intent to treat | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 5.2 | 95% Confidence Interval 3.1 to 9.0 | months | |
| Overall Survival | Arm 2, Comparator: Carboplatin + Paclitaxel | 4.0 | 95% Confidence Interval 2.8 to 6.2 | months | |
| To Determine Percentage of 1 Year Survival | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 26 | percentage of participants | ||
| To Determine Percentage of 1 Year Survival | Arm 2, Control: Carboplatin + Paclitaxel | 9 | percentage of participants |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Phase | STARTED | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 55 | |
| Treatment Phase | STARTED | Arm 2, Control: Carboplatin + Paclitaxel | 25 | |
| Treatment Phase | COMPLETED | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 18 | |
| Treatment Phase | COMPLETED | Arm 2, Control: Carboplatin + Paclitaxel | 7 | |
| Treatment Phase | NOT COMPLETED | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 37 | |
| Treatment Phase | NOT COMPLETED | Arm 2, Control: Carboplatin + Paclitaxel | 18 | |
| Maintenance Phase | STARTED | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 16 | |
| Maintenance Phase | STARTED | Arm 2, Control: Carboplatin + Paclitaxel | 0 | |
| Maintenance Phase | COMPLETED | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 2 | |
| Maintenance Phase | COMPLETED | Arm 2, Control: Carboplatin + Paclitaxel | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events236
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 6 | 51 | |
| other | Abdominal pain | Gastrointestinal disorders | Arm 2, Comparator: Carboplatin + Paclitaxel | 2 | 24 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 4 | 51 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Arm 2, Comparator: Carboplatin + Paclitaxel | 0 | 24 | |
| other | Alanine transferase increased | Investigations | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 4 | 51 | |
| other | Alanine transferase increased | Investigations | Arm 2, Comparator: Carboplatin + Paclitaxel | 0 | 24 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 16 | 51 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Arm 2, Comparator: Carboplatin + Paclitaxel | 3 | 24 | |
| other | Anemia | Blood and lymphatic system disorders | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 20 | 51 | |
| other | Anemia | Blood and lymphatic system disorders | Arm 2, Comparator: Carboplatin + Paclitaxel | 12 | 24 |
1 to 10 of 236Source ClinicalTrials.gov
See all 236 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | ||
| Total, all-cause mortality | Arm 2, Comparator: Carboplatin + Paclitaxel | ||
| Total, other adverse events | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 50 | 51 |
| Total, other adverse events | Arm 2, Comparator: Carboplatin + Paclitaxel | 24 | 24 |
| Total, serious adverse events | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | 21 | 51 |
| Total, serious adverse events | Arm 2, Comparator: Carboplatin + Paclitaxel | 5 | 24 |
Source ClinicalTrials.gov
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Arm 1, Active: CA4P + Carboplatin + Paclitaxel vs Arm 2, Comparator: Carboplatin + Paclitaxel: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00507429
GET https://conductscience.org/api/trials/v1/NCT00507429/events?page=2